A Phase 3 interventional study of Secukinumab and Mycophenolate mofetil (MMF) in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), sponsored by Chinese PLA General Hospital. Not yet recruiting. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Chinese PLA General Hospital · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to evaluate the safety and efficacy of secukinumab versus mycophenolate mofetil in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system mediated primarily by antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG). Its clinical manifestations include optic neuritis (ON), acute transverse myelitis (ATM), acute disseminated encephalomyelitis (ADEM), and, more rarely, various forms of encephalitis. Data from several cohorts suggest that approximately 50% of adult patients with MOG-IgG relapse within the first two years of disease onset. No drug is currently approved by the FDA for MOGAD, and mycophenolate mofetil (MMF) is widely used as a conventional first-line maintenance immunosuppressant. Interleukin-17A (IL-17A), a key cytokine secreted by T helper 17 (Th17) cells, participates in downstream inflammatory responses, promotes Th17 cell differentiation through a positive feedback loop, and drives the differentiation of B cells into antibody-producing plasma cells. Studies have shown that peripheral blood Th17 cell levels are significantly higher in MOGAD patients, in both the acute and remission phases, than healthy controls. Patients with higher peripheral Th17 cell counts tend to have more severe disease and higher relapse rates, suggesting that IL-17A may contribute to the pathogenesis and progression of MOGAD. Secukinumab, a humanized monoclonal antibody against the IL-17A has shown beneficial clinical effects and reduction of the risk of relapses in some patients with relapsing MOGAD in our previous pilot study. However, the efficacy and safety of secukinumab in relapsing MOGAD warrants further clinical trials.
23 studies on the registry are indexed under Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; 20 are open to participants now.
This study's planned enrollment of 130 is close to the median of 126 across 11 interventional studies indexed under Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Browse Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease studies →Chinese PLA General Hospital is the lead sponsor of 570 studies on the registry; 207 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants must meet all of the following conditions in order to be enrolled:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300 mg s.c. (2 x 1 mL pre-filled syringe (PFS) 150 mg secukinumab) at Baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a protocol-specified prednisone taper regimen.
Drug: Secukinumab
Mycophenolate mofetil (MMF) 1000 mg p.o. twice daily (Pediatric dose: 500-750 mg/m² body surface area, administered orally in two divided doses). MMF will be given in combination with a protocol-specified prednisone taper regimen.
Drug: Mycophenolate mofetil (MMF)
Secukinumab 300 mg s.c. (2 x 1 mL pre-filled syringe (PFS) 150 mg secukinumab) at Baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a protocol-specified prednisone taper regimen.
Mycophenolate mofetil (MMF) 1000 mg p.o. twice daily (Pediatric dose: 500-750 mg/m² body surface area, administered orally in two divided doses). MMF will be given in combination with a protocol-specified prednisone taper regimen.
the time to first adjudicated relapse from randomization
An adjudicated relapse was defined by the protocol and positively adjudicated by the independent adjudication committee.
Time frame: Baseline, Up To 48 Weeks or End of Study
Annualized relapse rate during any exposure to the experimental drugs
The adjudicated annualized relapse rate (ARR) was defined as the total number of protocoldefined relapses divided by the corresponding observation period in years. Before randomization, ARR was calculated as the total number of relapses before randomization divided by the time from first relapse to randomization (in days) and then divided by 365 for patients with a disease duration of ≤2 years, or as the number of relapses within the 2 years before randomization divided by 2 for patients with a disease duration of \>2 years.
Time frame: Baseline, Up To 48 Weeks or End of Study
Relapse-free and steroid-free remission state at EOS visit
Relapse-free and steroid-free remission state at EOS visit
Time frame: 48 Weeks or End of Study
Change from baseline in dosage of prednisone at EOS visit
Change from baseline in dosage of prednisone at EOS visit
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in EDSS score at EOS visit
Disease-related disability was measured by the EDSS. The EDSS was an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in active MRI lesions at EOS visit
active MRI lesions: new Gd-enhancing lesions
Time frame: Baseline, Up To 48 Weeks or End of Study
Treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (TESAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship A SAE was any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in Low-contrast visual acuity in affected eyes by optic neuritis at EOS visit
Change from baseline in Low-contrast visual acuity in affected eyes by optic neuritis at EOS visit
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in visual acuity in affected eyes by optic neuritis at EOS visit
om baseline in visual acuity in affected eyes by optic neuritis at EOS visit
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in peripapillary retinal nerve fiber layer (pRNFL) at EOS visit
Change from baseline in peripapillary retinal nerve fiber layer (pRNFL) thickness, measured in μm by optical coherence tomography (OCT)
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in ganglion cell and inner plexiform layer (GCIPL) at EOS visit
Change from baseline in ganglion cell-inner plexiform layer (GCIPL) thickness at the EOS visit, measured in μm by OCT
Time frame: Baseline, Up To 48 Weeks or End of Study
Change from baseline in ganglion cell and serum MOG-LgG titers at EOS visit
Change from baseline in serum MOG-IgG titers measured by live cell-based assay at the EOS visit
Time frame: Baseline, Up To 48 Weeks or End of Study
No study locations are listed for this record.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease →
Chinese PLA General Hospital →